Melanoma treated with adoptive T cell therapy (ACT) (Figures 9A–C), melanoma treated with pembrolizumab, an anti-PD-1 antibody (Figures 9D–F), melanoma treated with anti-CTLA4 and ant-PD1 therapy (Figures 9G–I), NSCLC treated with nivolumab or pembrolizumab, an anti-PD-1 antibody (Figures 9J–L), advanced urothelial cancer treated with atezolizumab, an anti-PD-L1 antibody (Figures 9M–O) were used to validate the performance of risk score in predicting prognosis and efficacy of immunotherapy. This evidence concerns the gene CD274 and melanoma.